Stock CLNN CLENE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Clene Inc.

Equities

CLNN

US1856341029

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 02:00:00 04/05/2024 am IST 		5-day change 1st Jan Change
0.4349 USD -0.41% Intraday chart for Clene Inc. +27.95% +46.63%
16/04 Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension Study Results at the 2024 American Academy of Neurology Annual Meeting in Denver CI
15/03 Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 21.48 535.1 255 73.82 38.09 55.86 - -
Enterprise Value (EV) 1 21.48 535.1 255 76.18 38.09 28.66 10.36 25.56
P/E ratio -80.6 x -27.8 x -25.6 x -2.17 x -0.63 x -1.44 x -1.53 x -2.12 x
Yield - - - - - - - -
Capitalization / Revenue - 2,598 x 353 x 156 x 58.2 x 126 x 10.2 x 1.42 x
EV / Revenue - 2,598 x 353 x 161 x 58.2 x 64.5 x 1.9 x 0.65 x
EV / EBITDA - - - -1.61 x -0.98 x -0.71 x -0.18 x -0.78 x
EV / FCF - - - -1.72 x - -0.7 x -0.18 x -1.68 x
FCF Yield - - - -58% - -143% -548% -59.5%
Price to Book - - - 20 x - 1.81 x 1.89 x 2.17 x
Nbr of stocks (in thousands) 2,049 59,393 62,204 73,820 1,28,416 1,28,434 - -
Reference price 2 10.48 9.010 4.100 1.000 0.2966 0.4349 0.4349 0.4349
Announcement Date 10/09/20 29/03/21 11/03/22 13/03/23 13/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - 0.206 0.723 0.473 0.654 0.444 5.46 39.33
EBITDA 1 - - - -47.39 -38.84 -40.2 -58.95 -32.65
EBIT 1 -16.33 -20.21 -49.98 -48.41 -40.54 -40.71 -49.17 -38.49
Operating Margin - -9,812.62% -6,912.59% -10,234.46% -6,198.78% -9,168.69% -900.49% -97.86%
Earnings before Tax (EBT) 1 - -18.87 -10.17 -29.92 -49.5 -43 -49.51 -38.09
Net income 1 - -19.28 -9.74 -29.92 -49.5 -43 -49.51 -38.09
Net margin - -9,357.77% -1,347.16% -6,325.16% -7,569.42% -9,684.91% -906.75% -96.85%
EPS 2 -0.1300 -0.3238 -0.1600 -0.4600 -0.4700 -0.3020 -0.2840 -0.2050
Free Cash Flow 1 - - - -44.19 - -41.1 -56.8 -15.2
FCF margin - - - -9,342.49% - -9,256.76% -1,040.29% -38.64%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 10/09/20 29/03/21 11/03/22 13/03/23 13/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 0.11 0.199 0.03 0.035 0.174 0.234 0.107 0.269 0.108 0.17 0.123 0.123 0.126 0.126 0.1
EBITDA 1 - - -13.14 -13.31 -9.572 -11.37 -10.33 -9.894 -9.103 -9.508 -9.6 -10.1 -10.2 -10.35 -
EBIT 1 -10.45 -14.06 -13.34 -13.6 -9.805 -11.67 -10.73 -10.34 -9.542 -9.93 -9.578 -9.716 -9.962 -10.46 -8.9
Operating Margin -9,500% -7,064.32% -44,453.33% -38,842.86% -5,635.06% -4,988.46% -10,029.91% -3,842.38% -8,835.19% -5,841.18% -7,786.79% -7,898.98% -7,905.95% -8,304.56% -8,900%
Earnings before Tax (EBT) 1 28.88 4.208 -13.35 -4.534 -10.98 -1.054 -11.77 -25.14 -2.418 -10.17 -10.37 -10.68 -10.92 -11.08 -9
Net income 1 28.94 4.423 -13.35 -4.534 -10.98 -1.054 -11.77 -25.14 -2.418 -10.17 -10.37 -10.68 -10.92 -11.08 -9
Net margin 26,312.73% 2,222.61% -44,513.33% -12,954.29% -6,308.05% -450.43% -11,000% -9,346.84% -2,238.89% -5,984.12% -8,431.06% -8,683.41% -8,664.44% -8,792.86% -9,000%
EPS 2 0.4200 0.0700 -0.2100 -0.0700 -0.1700 - -0.1500 -0.2900 -0.0200 -0.0600 -0.0800 -0.0760 -0.0760 -0.0720 -0.0700
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 08/11/21 11/03/22 09/05/22 15/08/22 07/11/22 13/03/23 12/05/23 14/08/23 07/11/23 13/03/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - 2.36 - - - -
Net Cash position 1 - - - - 27.2 45.5 30.3
Leverage (Debt/EBITDA) - - -0.0497 x - - - -
Free Cash Flow 1 - - -44.2 - -41.1 -56.8 -15.2
ROE (net income / shareholders' equity) - - -378% - -143% -136% -31.6%
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 2 - - 0.0500 - 0.2400 0.2300 0.2000
Cash Flow per Share 2 - - -0.6000 - -0.2400 -0.2200 -0.0500
Capex 1 0.39 1.33 5.18 - 2 2 2
Capex / Sales 187.86% 184.23% 1,094.93% - 450.45% 36.63% 5.08%
Announcement Date 29/03/21 11/03/22 13/03/23 13/03/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Clene Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.4349 USD
Average target price
5 USD
Spread / Average Target
+1,049.69%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CLENE INC. Stock Clene Inc.
+46.63% 55.86M
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 105B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 104B
ARGENX SE Stock argenx SE
+4.40% 22.94B
BIONTECH SE Stock BioNTech SE
-12.15% 22.34B
GENMAB A/S Stock Genmab A/S
-4.36% 19.25B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.08B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.96B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.79% 14.16B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.63B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CLNN Stock
  4. Financials Clene Inc.